Universitätsklinik für Neurologie
 

Neurovaskuläre Arbeitsgruppe

 

Mission Statement:

Unserer Arbeitsgruppe obliegt die Akut- und Langzeitbetreuung von Patienten mit Schlaganfällen und die Koordination des tirolweiten integrativen Schlaganfallnetzwerks.

Unsere wissenschaftliche Schwerpunkte liegen in der klinischen Atherosklerose-Forschung (Bruneck-Studie), der Gefäßalterung (VASCage) und der Akuttherapie des Schlaganfalls.

 

Clinical Stroke Research

 Clinical Stroke Care 

VASCage

Proof-ATHERO

 

Aktuelles: 

       
 Stefan_Kiechl

Stefan Kiechl wird am Europäischen Schlaganfallkongress ESOC der renommierte Research Excellence Award der European Stroke Organisation für seine Leistungen in der Schlaganfallforschung verliehen.

 

Am 07.11.2016 erhielt er die höchste wissenschaftliche Auszeichnung des Landes Tirols - den Tiroler Landespreis für Wissenschaft.

  peter_willeit_aek_preis

Peter Willeit erhält den Preis der Ärztekammer für Tirol 2015 für die Arbeit Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study.

 

Zudem erhielt der den Förderpreis des Landes Tirol 2016 und den Wissenschaftspreis der Österreichischen Schlaganfall-Gesellschaft 2017 für seine Arbeiten zu den natriuretischen Peptiden.

         
thomas-toell-istanbul

Thomas Töll schließt Patient 1.600 in die prospektive randomisierte Interventionsstudie Stroke Card ein.

 

  award-of-excellence-2015-pechlaner-small

Raimund Pechlaner erhält einen Staatspreis "Award of Excellence" für seine Dissertation Role of iron in atherogenesis and its clinical sequelae stroke and myocardial infarction.

 

Archiv

       

 

Leiter:

Univ.-Prof. Dr. Johann Willeit

Univ.-Prof. Dr. Stefan Kiechl (Präsident der österreichischen Schlaganfall-Gesellschaft)

Mag. Manuela Bock-Bartl (Projektmanagerin des Projektes VASCage)

 

Mitarbeiter:

Dr. Michael Knoflach, Dr. Martin Furtner, Dr. Christoph Schmidauer, Dr. Martin Sojer, Dr. Christian Böhme, Dr. Gerhard Klingenschmid,  

Dr. Karin Willeit, Dr. Raimund Pechlaner, Dr. Peter Willeit, Dr. Thomas Töll, Dr. Lukas Mayer, Dr. Lena Tschiderer

 

 Gruppenfoto neu

 

 

Die junge Arbeitsgruppe und ihre Projekte (v.l.n.r):

  • Dr. Raimund Pechlaner: Protein signatures of cardiometabolic diseases
  • Dr. Karin Willeit: Kurz- und Langzeitprädiktion kardiovaskulärer Erkrankungen: Innovative Biomarker und Risiko-Scores (TIROL-Score)
  • Dr. Thomas Töll: Post-stroke disease management: Nutzen und Effizienz einer intensivierten Schlaganfallnachsorge
  • Dr. Lukas Mayer (nicht im Bild): Prädiktoren eines Rezidivs nach spontaner zervikaler Dissektion
  • Dr. Gerhard Klingenschmid (nicht im Bild): Einfluss von Lebensstil, Risikofaktoren und Erkrankungen auf die Lebensqualität älterer Menschen
  • Dr. Lena Tschiderer (nicht im Bild): Atherosclerosis as a determinant of life expectancy: Association of intima-media thickness with all-cause mortality
  • Dr. Christian Böhme (nicht im Bild): Post Stroke Disease Management: Clinical Outcome and Quality of Life

 

 

 

Preise

 

 

 

 

Ausgewählte Publikationen

Willeit J, Geley T, Schöch J, Rinner H, Tür A, Kreuzer H, Thiemann N, Knoflach M, Toell T, Pechlaner R, Willeit K, Klingler N, Praxmarer S, Baubin M, Beck G, Berek K, Dengg C, Engelhardt K, Erlacher T, Fluckinger T, Grander W, Grossmann J, Kathrein H, Kaiser N, Matosevic B, Matzak H, Mayr M, Perfler R, Poewe W, Rauter A, Schoenherr G, Schoenherr HR, Schinnerl A, Spiss H, Thurner T, Vergeiner G, Werner P, Wöll E, Willeit P, Kiechl S

Thrombolysis and clinical outcome in patients with stroke after implementation of the Tyrol Stroke Pathway: a retrospective observational study

The Lancet Neurology 2015;14:48-56

This paper was awarded with the INTEGRI-AWARD

 

During the period of implementation of our comprehensive stroke management programme, thrombolysis administration increased and clinical outcome significantly improved, although mortality did not change. We hope that these results will guide health authorities and stroke physicians elsewhere when implementing similar programmes for patients with stroke.

 

 

 Thrombolysis administration in the nine counties of Tyrol in 2010 (A) and 2013 (B)

 

 

Stegemann C*, Pechlaner R*, Willeit P, Langley S, Mangino M, Mayr U, Menni C, Moayyeri A, Santer P, Rungger G, Spector TD, Willeit J, Kiechl S, Mayr M

*These authors contributed equally

Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck Study

Circulation 2014;129:1821-1831

 

This study applied mass spectrometry-based lipidomics profiling to population-based cohorts and identified molecular lipid signatures for cardiovascular disease. Molecular lipid species constitute promising new biomarkers that outperform the conventional biochemical measurements of lipid classes currently used in the clinics.

 

 

associations-of-lipid-species-with-CVD

 

 

 

Natriuretic Peptides Studies Collaboration, Willeit P et al.

 

Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis.

 

Lancet Diabetes Endocrinol 2016;10:840-9

 

In an evaluation of 40 prospective studies with a total of 95,617 study participants, Peter Willeit showed that the increased levels of the natriuretic peptide NT-proBNP was associated with an increased risk of cardiovascular diseases. The strength of this association was comparable to that of HDL cholesterol (Figure). This work also describes the fact that the measurement of NT-proBNP in addition to the detection of standard risk factors significantly improves the prediction and thus can lead to an optimization of the primary prevention of these diseases.

 

  Peter Abbildung

 

 

 

 

 

 

Kiechl S, Wittmann J, Giaccari A, Knoflach M, Willeit P, Bozec A, Moschen AR, Muscogiuri G, Sorice GP, Kireva T, Summerer M, Wirtz S, Luther J, Mielenz D, Billmeier U, Egger G, Mayr A, Oberhollenzer F, Kronenberg F, Orthofer M, Penninger JM, Meigs JB, Bonora E, Tilg H, Willeit J, Schett G.

Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus

Nature Medicine 2013;19:358-363

 

This study provides strong evidence for a role of RANKL signaling in the pathogenesis of hepatic insulin resistance and T2DM, provides a link between inflammation and disrupted glucose homeostasis and holds promise for the future development of new therapeutic and preventive approaches.

 

 

 

 

 

 

 

The Emerging Risk Factors Collaboration

 

C-reactive protein, fibrinogen, and cardiovascular disease prediction
N Engl J Med 2012;367:1310-1320

Diabetes mellitus, fasting glucose, and risk of cause-specific death

N Engl J Med 2011;364:829-841

 

J. Willeit and S. Kiechl are members of the writing committee of the ERFC which has published more than ten individual data meta-analysis on cardiovascular risk factors and risk prediction. The two papers presented here elaborate the association between diabetes and cause-specific mortality and the usefulness of high-sensitivity CRP in cardiovascular risk prediction.

 

NEJM

 

 

Pechlaner R, Tsimikas S, Yin X, Willeit P, Baig F, Santer P, Oberhollenzer F, Egger G, Witztum JL, Alexander VJ, Willeit J, Kiechl S, Mayr M.

Very-Low-Density Lipoprotein-Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III.

 

J Am Coll Cardiol 2017;7:789-800

 

This study reports a strong association of VLDL associated Apolipoproteins with incident cardiovascular disease and may be the basis for a new therapy targeting these Apolipoproteins. Valentin Fuster considered this manuscript as one of the best in his period as the Editor-in-Chief of JACC.

 

 

 Raimund-APOC-III

 

 

Langley SR, Willeit K, Didangelos A, Matic LP, Skroblin P, Barallobre-Barreiro J, Lengquist M, Rungger G, Kapustin A, Kedenko L, Molenaar C, Lu R, Barwari T, Suna G, Yin X, Iglseder B, Paulweber B, Willeit P, Shalhoub J, Pasterkamp G, Davies AH, Monaco C, Hedin U, Shanahan CM, Willeit J, Kiechl S, Mayr M.

Extracellular matrix proteomics identifies molecular signature of symptomatic carotid plaques.

J Clin Invest 2017;4:1546-1560

 

This study is the first to identify a proteom signature of instable plaques.

  Extracellula Matrix_Karin

 

 

 

 

Lang C, Seyfang L, Ferrari J, Gattringer T, Greisenegger S, Willeit K, Toell T, Krebs S, Brainin M Kiechl S, Willeit J, Lang W, Knoflach M; Austrian Stroke Registry Collaborators.

Do Women With Atrial Fibrillation Experience More Severe Strokes? Results From the Austrian Stroke Unit Registry.

Stroke 2017;48:778-780

 

It is a well-established fact that women with atrial fibrillation are at increased risk of stroke, yet it is unknown, if there is a sex difference also in stroke severity. We address this question analyzing more than 70.000 patients documented in the Austrian Stroke Unit Registry.

 

        Women with artrial fibrilation _ Michael

 

 

Alle Publikationen
Pubmed

Klinische Studien

Aktuell: RESPECT-ESUS, Stroke Card

Abgeschlossen: SPARCL, MATCH, DIAS I/II, SPACE, CHARISMA, ECASS I/III, CRESCENDO, PERFORM, TRA 2°P TIMI 50, DIAS III

Links

 Tiroler Schlaganfallpfad

 Projektbericht

 Projektbericht

 Folder

 Folder

Österreichische Schlaganfall-Gesellschaft

  OEGSF

 

 

Bruneck-Studie

 Bruneck

Publikationen

 

 

Rezente Bücher und Buchbeiträge:

US

Ultrasound and Carotid Bifurcation Atherosclerosis

Autoren: Andrew Nicolaides, Kirk W. Beach, Efthyvoulos Kyriacou, Constantinos S. Pattichis

Beiträge: Stefan Kiechl, Philipp Werner, Michael Knoflach, Johann Willeit

Verlag: Springer

Link

Nach einem Schlaganfall

Nach einem Schlaganfall

Autoren: Stefan Kiechl, Wolfgang Lalouschek, Wilfried Lang

Verlag: Holzhausen

Link

US PNS

High-Resolution Sonography of the Peripheral Nervous System

Autoren: Hannes Gruber, Peter Kovacs, Stefan Kiechl, Gerd Bodner, Hildegunde Piza-Katzer

Verlag: Springer

Link

 

 

Neurovaskuläre Arbeitsgruppe – Universitätsklinik für Neurologie

Medizinische Universität Innsbruck – Anichstraße 35 – 6020 Innsbruck

Tel. +43 (0)512 504 23903 – Fax. +43 (0)512 504 23987

© Medizinische Universität Innsbruck - Alle Rechte vorbehaltenMail an i-master - Letzte Änderung: 25.7.2017, 15:35:20ximsTwitter LogoFacebook Logo